A Survey of ACRO Member Companies Shows How Risk-Based Approaches Are Used in Clinical Trials
In early 2022, ACRO conducted the third consecutive year of its annual landscape survey, and this report highlights key findings. The aim of the survey is to answer ACRO member companies’ and global regulators’ interest in understanding how risk-based monitoring (RBM) and the larger framework of risk-based quality management (RBQM) are being adopted across the clinical trial industry. Conversations with FDA helped inform survey content and development.